Upstream Bio, Inc. (UPB) Stock Price & Analysis
Upstream Bio, Inc. (UPB) rose 3.72% to USD 6.69 as of June 10, 2026 at 03:13 UTC, according to Nexqual real-time market data.
UPB last closed at USD 6.45; the session ranged USD 6.42–6.78 on volume of 489,743 shares. Market capitalization is $364.07M, with a 52-week range of USD 6.41–33.68 (NMS). Source: Nexqual, June 10, 2026 at 03:13 UTC.
Key Statistics (as of June 10, 2026 at 03:13 UTC)
| Price | USD 6.69 |
|---|---|
| Change | ▲ 3.72% (up) |
| Previous Close | USD 6.45 |
| Open | USD 6.53 |
| Day Range | USD 6.42 – 6.78 |
| 52-Week Range | USD 6.41 – 33.68 |
| Volume | 489,743 shares |
| Market Cap | $364.07M |
| Exchange | NMS |
Technical Analysis (UPB)
Nexqual's technical model rates UPB "SELL" based on 2 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 03:13 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 28.97 (oversold) |
| vs SMA50 | Below (USD 8.96) |
| MACD | -0.63 (negative) |
Analyst Ratings (UPB)
Wall Street analysts rate UPB "Strong Buy" based on 8 analysts, with a mean price target of USD 41.63 (range USD 15–75), per Nexqual as of June 10, 2026 at 03:13 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 41.63 |
| High Target | USD 75 |
| Low Target | USD 15 |
| Buy / Hold / Sell | 8 / 1 / 0 |
Earnings (UPB)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD -0.75 |
| Revenue Estimate | $431,140 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.75 vs est -0.75 ▲ beat |
| 2025-12-31 | USD -0.78 vs est -0.7 ▼ miss |
| 2025-09-30 | USD -0.63 vs est -0.78 ▲ beat |
| 2025-06-30 | USD -0.74 vs est -0.61 ▼ miss |
Source: Nexqual, June 10, 2026 at 03:13 UTC.
Financials & Fundamentals (UPB)
| Total Revenue | $3.32M |
|---|---|
| Revenue Growth (YoY) | +82.70% |
| Gross Margin | +100.00% |
| Operating Margin | -4218.09% |
| Profit Margin | +0.00% |
| ROE | -41.83% |
| Debt / Equity | 0.37 |
| Current Ratio | 23.14 |
| Total Cash | $294.58M |
| Total Debt | $1.11M |
| Free Cash Flow | $-90.31M |
Source: Nexqual, June 10, 2026 at 03:13 UTC.
Financial Health Score (UPB)
Nexqual rates Upstream Bio, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 03:13 UTC.
| Growth | Strong — Revenue +20% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $295M cash vs $1M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$90M, burning cash |
| Efficiency | Critical — ROE -42%, ROA -27.8% |
Ownership (UPB)
| Insider Ownership | +14.88% |
|---|---|
| Institutional Ownership | +90.10% |
| Shares Outstanding | 54.42M |
| Float | 34.97M |
| Short % of Float | +10.32% |
Source: Nexqual, June 10, 2026 at 03:13 UTC.
Leadership (UPB)
Upstream Bio, Inc. is led by E. Rand Sutherland M.D., M.P.H. (age 55), CEO & Director, per Nexqual as of June 10, 2026 at 03:13 UTC.
| CEO & Director | E. Rand Sutherland M.D., M.P.H. (age 55) |
|---|---|
| CFO & COO | Michael Paul Gray (age 54) |
| Chief Technology Officer | Stacy Price M.S., P.M.P. (age 56) |
| Director of Corporate Communications & Investor Relations | Meggan Buckwell |
| Senior Vice President of People & Culture | Lisa Fiering |
Major Backers & Investors (UPB)
Notable institutional backers of Upstream Bio, Inc. include FMR, LLC, Fidelity, Orbimed Advisors LLC., according to Nexqual as of June 10, 2026 at 03:13 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 14.89% |
| Fidelity | 10.56% |
| Orbimed Advisors LLC. | 10.46% |
| Decheng Capital LLC | 5.01% |
| Enavate Sciences Gp, LLC | 4.52% |
| Y Intercept (Hong Kong) Ltd | 1.84% |
| Federated Hermes, Inc. | 1.8% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 7.62% |
| Vanguard Group | 6.79% |
| Geode Capital | 1.75% |
Source: Nexqual, June 10, 2026 at 03:13 UTC.
From Upstream Bio, Inc.'s Latest SEC 10-K Filing (filed 2026-03-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Approximately 350 million people live with asthma around the world, including more than 25 million Americans.
- The major asthma markets, including the United States, France, Spain, Germany, Italy, the United Kingdom ("UK") and Japan, have estimated annual sales of approximately $7.5 billion for 2023 with a compound annual growth rate ("CAGR") of approximately 5.9% through 2032.
- Tezepelumab is projected to reach peak global annual sales of over $3.0 billion for severe asthma alone in 2032, and had achieved more than 20% of new to brand share of prescriptions in the United States in its first commercial year.   12   Taken together, we believe the strength of the biologic market has demonstrated there is room for multiple entrants into the market and the opportunity for rapid acceleration for market share.
- Our team     6   We have built a team with deep experience and a strong track record of execution.
Partnerships
- Dupilumab alone has an annual global sales estimate for the treatment of CRSwNP of up to $1.5 billion by 2030 according to third-party research analyst reports.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MBX | MBX Biosciences, Inc. | USD 29.87 | ▼ 1.35% |
| BCAX | Bicara Therapeutics Inc. | USD 20.56 | ▲ 2.8% |
| ZBIO | Zenas BioPharma, Inc. | USD 18.42 | ▲ 5.44% |
| RAPP | Rapport Therapeutics, Inc. | USD 35.84 | ▼ 0.72% |
| SEPN | Septerna, Inc. | USD 31.01 | ▼ 0.45% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:13 UTC. This page is informational and not investment advice.